Cytokinetics (NASDAQ:CYTK) Shares Down 6.6% - Here's What Happened

Key Points

• Cytokinetics shares fell 6.6% to $75.97 in Friday trading, despite the company reporting second-quarter revenue of $28.6 million and an adjusted loss of $1.50 per share, both better than analysts’ expectations.
• Investor concerns include a 57.1% year-over-year revenue decline, widening losses, $159.8 million in quarterly operating cash outflow, and continued insider selling.
• Wall Street remains broadly optimistic: analysts have a “Moderate Buy” consensus rating and an average price target of $100.85, while the company ended the quarter with approximately $1.17 billion in cash and equivalents.

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report)'s share price fell 6.6% on Friday . The stock traded as low as $76.40 and last traded at $75.97. Approximately 1,067,949 shares changed hands during mid-day trading, a decline of 51% from the average session volume of 2,162,348 shares. The stock had previously closed at $81.37.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Analyst confidence increased: Needham raised its price target from $102 to $112 and reiterated a “Buy” rating, while Citizens JMP lifted its target from $105 to $110 and assigned a “Market Outperform” rating. The new targets imply roughly 44%–46% upside from the recent share price. The Fly analyst price target report
• Positive Sentiment: Second-quarter revenue and EPS beat expectations: Cytokinetics reported revenue of $28.6 million versus the approximately $17.6 million consensus estimate. Its loss of $1.50 per share was narrower than the expected $1.63 loss, providing a modest positive surprise for investors. Cytokinetics second-quarter 2026 results
• Neutral Sentiment: The balance sheet remains well funded but requires monitoring: Cytokinetics ended the quarter with approximately $1.17 billion in cash and equivalents, although operating cash outflow was $159.8 million. The company reported a $179.2 million operating loss and a $198.8 million net loss, underscoring the ongoing cost of advancing its pipeline.
• Negative Sentiment: Revenue declined sharply year over year: Quarterly revenue fell 57.1% from the prior-year period, while losses widened from $1.12 per share to $1.50 per share. Separately, third-party data showed 49 insider sales and no insider purchases over the past six months, which may add to investor caution. Cytokinetics earnings and insider activity report

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CYTK shares. HC Wainwright boosted their price objective on Cytokinetics from $136.00 to $140.00 and gave the stock a "buy" rating in a report on Monday, May 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cytokinetics in a research note on Friday, July 17th. Needham & Company LLC lifted their price target on Cytokinetics from $102.00 to $112.00 and gave the stock a "buy" rating in a report on Friday. JPMorgan Chase & Co. lifted their price target on Cytokinetics from $92.00 to $97.00 and gave the stock an "overweight" rating in a report on Tuesday, May 12th. Finally, Stifel Nicolaus boosted their price target on Cytokinetics from $98.00 to $108.00 and gave the company a "buy" rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Cytokinetics presently has an average rating of "Moderate Buy" and a consensus target price of $100.85.

Cytokinetics Trading Down 5.8%

The stock's 50-day simple moving average is $78.91 and its 200-day simple moving average is $70.86. The stock has a market cap of $9.54 billion, a price-to-earnings ratio of -11.19 and a beta of 0.38.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, topping the consensus estimate of ($1.63) by $0.13. The business had revenue of $28.62 million for the quarter, compared to the consensus estimate of $17.59 million. During the same period in the prior year, the business posted ($1.12) earnings per share. The firm's revenue for the quarter was down 57.1% compared to the same quarter last year. On average, equities research analysts forecast that Cytokinetics, Incorporated will post -6.2 earnings per share for the current year.

Insider Buying and Selling

In other Cytokinetics news, EVP Andrew Callos sold 14,000 shares of the firm's stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $79.88, for a total transaction of $1,118,320.00. Following the transaction, the executive vice president owned 58,555 shares in the company, valued at $4,677,373.40. This trade represents a 19.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of Cytokinetics stock in a transaction on Monday, July 27th. The shares were sold at an average price of $80.87, for a total value of $606,525.00. Following the completion of the transaction, the chief executive officer directly owned 377,820 shares of the company's stock, valued at $30,554,303.40. This represents a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 115,179 shares of company stock worth $9,126,054. 2.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Tema ETFs LLC lifted its position in Cytokinetics by 174.6% during the second quarter. Tema ETFs LLC now owns 22,413 shares of the biopharmaceutical company's stock worth $1,909,000 after purchasing an additional 14,251 shares during the period. E. Ohman J or Asset Management AB grew its stake in Cytokinetics by 1.3% during the second quarter. E. Ohman J or Asset Management AB now owns 304,611 shares of the biopharmaceutical company's stock worth $25,950,000 after buying an additional 3,849 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in Cytokinetics by 63.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company's stock valued at $34,502,000 after buying an additional 157,700 shares during the period. GAMMA Investing LLC increased its holdings in Cytokinetics by 12.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,487 shares of the biopharmaceutical company's stock valued at $212,000 after buying an additional 266 shares during the period. Finally, Seven Fleet Capital Management LP raised its position in shares of Cytokinetics by 492.8% in the 1st quarter. Seven Fleet Capital Management LP now owns 61,269 shares of the biopharmaceutical company's stock valued at $4,038,000 after buying an additional 50,934 shares in the last quarter.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source